Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Q3 2020 Earnings Presentation
27 slides from Bioporto A/s's earnings presentation, Nov 18, 2020
Slide 1: Interim report, Q1-Q3 2020
Interim report, Q1-Q3 2020 BioPorto November 18, 2020 © Copyright BioPorto
Slide 2: Forward-Looking Statements
Forward-Looking Statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company”) and any further information that may be made available in connection with the subject matter contained her
Slide 3: Agenda
1 Highlights from Q3 2020 Agenda 2 Q1-Q3 2020 Financial Results 3 NGAL Regulatory Strategy & Status 4 gRAD – COVID rapid test 5 2020 Milestones 6 Appendix: About BioPorto 3
Slide 4: Highlights from Q1-Q3 2020
Highlights from Q1-Q3 2020 © Copyright BioPorto 4
Slide 5: Highlights from Q1-Q3 2020
Highlights from Q1-Q3 2020 • Proof-of-concept for BioPorto’s Rapid Point-of-Care Test for COVID-19 – patient enrollment will start this week, clinical trials to be concluded by end-2020 • Enrollment continues in US for Pediatric Clinical Trial of The NGAL Test, but second COVID-19 wave restricts hos
Slide 6: Q1-Q3 2020 Financials Results
Q1-Q3 2020 Financials Results © Copyright BioPorto 6
Slide 7: Continued growth in product sales of The NGAL Test in Q3 2020 driven by ROW
Continued growth in product sales of The NGAL Test in Q3 2020 driven by ROW Revenue by Product Category (DKKm) +2%* U.S. NGAL 2.7 2.7 Q3 2019 2.3 Q3 2020 Revenue from RUO use of The NGAL Test in US in Q3 2020 vs. Q3 2019 1.7 ROW NGAL 1.4 +80% 0.3 0.2 Revenue from ROW product sales of 0.1 The NGAL Te
Slide 8: Product sales of The NGAL Test up 58% YoY as sales remain unaffected by COVID-19
Product sales of The NGAL Test up 58% YoY as sales re main unaffected by COVID-19 Revenue by Product Category (DKKm) NGAL Product sales by Quarter (LTM, DKKm) NGAL 9.8 8.1 Q1-Q3 2019 Q1-Q3 2020 +68% 14 14 7.4 11 10 4.4 3.9 10 9 10 9 8 1.1 7 0.7 Product sales, The NGAL Test 0.3 6 NGAL ELISA kits Anti
Slide 9: Fully guaranteed and oversubscribed rights issue with proceeds of DKK 93.6 million
Fully guaranteed and oversubscribed rights issue with proceeds of DKK 93.6 million Fully guaranteed rights issue initiated in September 2020 completed in October 2020 with proceeds of DKK 93.6 million • A total of 66,645,476 new shares at a subscription price of DKK 1.60 per share offered (1 pre- em
Slide 10: Total cash position to fund important milestones on NGAL and gRAD
Fully Subscribed Rights Offering Total cash position to fund important milestones on NGAL and gRAD Developing new indications using the gRAD platform, expectedly within the areas of COVID-19, Sepsis and Inflammation DKK 15m Developing the Company’s U.S. organization Funding of current operations, in
Slide 11: NGAL Regulatory Strategy & Status
NGAL Regulatory Strategy & Status © Copyright BioPorto 11
Slide 12: Regulatory strategy for The NGAL Test
Regulatory strategy for The NGAL Test Pediatrics Adults Additional Indications • Nephrotoxicity − Oncology − Cardiology 1 in 4 affected with AKI during hospitalization 1 in 5 adults affected with AKI − Diabetes (ICU)31 during a hospital episode of care32 − Transplant − Autoimmune Predict AKI Risk in
Slide 13: Pediatric analytical trials on track – Second wave COVID-19 restrictions delays enrollment
Pediatric analytical trials on track – Second wave COVID-19 restrictions delays enrollment • Prospective trial to establish and validate the performance of The NGAL Test • Pediatric population (≥3 months to <22 years old), urine samples • Patients admitted to the ICU with cardiovascular or respirato
Slide 14: gRAD platform COVID rapid test
gRAD platform COVID rapid test © Copyright BioPorto 14
Slide 15: Generic Rapid Assay Device (gRAD)
Generic Rapid Assay Device (gRAD) POSITIVE NEGATIVE BioPorto has developed a patented technology called the Generic Rapid Assay Device (gRAD). It is a lateral flow platform with no analyte-specific reagents on the strip. Instead, labelled capture antibodies and gold nanoparticle conjugated detection
Slide 16: Benefits of BioPorto's gRAD Solution
Benefits of BioPorto’s gRAD Solution Fast Versatile Easy Low Cost Scalable Short Flexible design No instruments, Simple format Design allows incubation time allows different fewer than 5 steps, with few rapid iteration <15 minutes sample types room temp stable components (days not weeks) and scale u
Slide 17: gRAD Platform for Product Development & Growth
gRAD Platform for Product Development & Growth NGALds Leveraging the gRAD platform, BioPorto is developing tests for NGAL as well as three emerging applications: COVIDds 1. NGALds: for near-patient assessment of kidney injury 2. Two COVID-19 assays: a viral diagnostic test and a gRAD serology-based
Slide 18: Viral COVIDds
Unique opportunity to use gRAD technology Viral COVIDds Product Format Update & Next Steps • Indication: Screen patients suspected of • Antibody development & testing - ongoing COVID-19 infection for active virus • Antibody selection & optimization - ongoing • Semi-quantitative, rapid immunoassay de
Slide 19: COVID-19: Laboratory Testing (YTD)
COVID-19: Laboratory Testing (YTD) • Antibodies to the SARS-CoV-2 spike protein developed and characterized • Antibodies transferred to ELISA and gRAD technologies Control line • ELISA and gRAD prototypes developed • On-going design optimization, e.g., using more Test line sensitive laboratory techn
Slide 20: Customer Segments, Value Proposition, Key Benefits
Customer Segments, Value Proposition, Key Benefits Customer Segments Governmental Value Proposition Institutions Detection of active SARS-CoV-2 virus in minimally invasive samples (saliva, nasal Private swabs) using a lateral flow device that leverages high specifity antibodies to the Organizations
Slide 21: 2020 Milestones
2020 Milestones © Copyright BioPorto 21
Slide 22: Targeted 2020 Milestones
Clinical, regulatory and commercial Targeted 2020 Milestones • Finalize collection of additional patient data for the FDA application of The NGAL Test for pediatrics and submit for clearance in Q1 2021 • Collect supplementary data to support submission of an application for The NGAL Test in adults •
Slide 23: Financial calendar 2021
Financial calendar 2021 March 17, 2021 Annual Report 2019 April 29, 2021 AGM May 12, 2021 Q1 2021 Results August 18, 2021 Q2 2021 Results November 17, 2021 Q3 2021 Results Contact: Ole Larsen (CFO) ol@bioporto.com © Copyright BioPorto
Slide 24: Appendix: About BioPorto
Appendix About BioPorto © Copyright BioPorto 24
Slide 25: About BioPorto
About BioPorto • Research assays ELISA Kits • Clinical diagnostics BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to • The NGAL Test transform novel research tools into clinically
Slide 26: Mission, Vision and Strategy
Mission, Vision and Strategy BioPorto helps healthcare providers improve patient management and outcomes with products that provide early and specific insights into significant clinical conditions. By 2025, we aspire to be one of the world’s leading companies in diagnostics for kidney health. Establ
Slide 27: Experienced International Management Team
BioPorto’s leadership Experienced International Management Team Peter Mørch Eriksen CEO CEO of BioPorto since July 2013 20+ years in medtech/life sciences, including CEO of Sense A/S and VP/GM of Medtronic Amy Winslow Ole Larsen Jan Kuhlmann President, Christopher Bird CFO COO BioPorto Diagnostics I